Buckman Laboratories (India) Profile
Key Indicators
- Authorised Capital ₹ 8.50 M
- Paid Up Capital ₹ 5.08 M
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Dec 2023
- Revenue Growth 11.08%
- Profit Growth -3.02%
- Ebitda 47.56%
- Net Worth 17.11%
- Total Assets 1.84%
About Buckman Laboratories (India)
Buckman Laboratories (India) Private Limited (BLIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 01 June 2005 and has a history of 19 years and eight months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2023. It's a company limited by shares with an authorized capital of Rs 8.50 M and a paid-up capital of Rs 5.08 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Dharmadhikary, Ramasamy Kannan, and Jigar Undavia serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24119TN2005PTC056486
- Company No.
056486
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Dec 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Buckman Laboratories (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Dharmadhikary  | Director | 15-Mar-2022 | Current |
Ramasamy Kannan  | Director | 31-Jul-2014 | Current |
| Jigar Undavia | Additional Director | 20-Apr-2024 | Current |
Financial Performance of Buckman Laboratories (India).
Buckman Laboratories (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.08% increase. The company also saw a slight decrease in profitability, with a 3.02% decrease in profit. The company's net worth Soared by an impressive increase of 17.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Buckman Laboratories (India)?
In 2022, Buckman Laboratories (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pakka LimitedRahul Dharmadhikary is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Buckman Laboratories (India)?
Buckman Laboratories (India) has a workforce of 131 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Buckman Laboratories (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Buckman Laboratories (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
